Gritstone bio(GRTS) - 2023 Q4 - Annual Results

Exhibit 99.1 Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates -- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone's personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC) remain expected in 1Q 2024 -- -- National Cancer Institute-led Phase 1 study evaluating Gritstone's "off-the-shelf" cancer vaccine, SLATE, combined with neoantigen cell therapy expected to begin in ...